Notice of Allowability	Application No.	Applicant(s)	
	08/347,748	748 KAUSHANSKY, KENNETH	
	Examiner	Art Unit	
	Prema M. Mertz	1646	
The MAILING DATE of this communication appeal all claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED in this apport or other appropriate communication IGHTS. This application is subject to	plication. If not included will be mailed in due course. TH	
1. X This communication is responsive to the amendment filed	<u>12/21/2006</u> .		
2. X The allowed claim(s) is/are 9-13, 16-22, 24, 26-31, renumb	pered, 1-5, 6-12, 13, 14-19, respectiv	<i>rely</i> .	
 3. Acknowledgment is made of a claim for foreign priority ura) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give 5. CORRECTED DRAWINGS (as "replacement sheets") must (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in to the deponsion of the deponsi	e been received. e been received in Application No cuments have been received in this of this communication to file a reply MENT of this application. iitted. Note the attached EXAMINER es reason(s) why the oath or declara st be submitted. son's Patent Drawing Review (PTO- s Amendment / Comment or in the C .84(c)) should be written on the drawi he header according to 37 CFR 1.121(sit of BIOLOGICAL MATERIAL r	national stage application from the complying with the requirements. 'S AMENDMENT or NOTICE OF stion is deficient. 948) attached Office action of the back) of d). must be submitted. Note the	
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	5. ☐ Notice of Informal F 6. ☑ Interview Summary Paper No./Mail Da 7. ☑ Examiner's Amenda 8. ☐ Examiner's Stateme 9. ☐ Other	(PTO-413), te	

Application/Control Number: 08/347,748

Art Unit: 1646

1. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Deborah A. Sawislak on 1/23/2007.

2. The application has been amended as follows:

IN THE CLAIMS:

In claim 18, line 11, after "thrombopoietin protein" insert -- and erythropoietin protein--.

In claim 18, line 11, delete "stimulates", substitute therefore --stimulate--.

In claim 18, line 12, after "lymphoid progenitors," delete "and erythropoietin,".

In claim 28, line 11, after "thrombopoietin protein" insert -- and erythropoietin protein--.

In claim 28, line 11, delete "stimulates", substitute therefore --stimulate--.

In claim 28, lines 12-13, after "lymphoid progenitors," delete "and erythropoietin,".

In claim 30, line 2, after "composition comprising", insert --an erythropoietin protein and a composition comprising--.

In claim 30, line 10, after "thrombopoietin protein" insert -- and erythropoietin protein--.

In claim 30, line 11, delete "stimulates", substitute therefore --stimulate--.

In claim 30, line 12, after "lymphoid progenitors," delete "and erythropoietin,".

Art Unit: 1646

3. Claims 9-13, 16-22, 24, 26-31, are allowable and have been renumbered 1-5, 6-12, 13, and 14-19 respectively.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (571) 272-0876. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached on (571) 272-0835.

Official papers filed by fax should be directed to (571) 273-8300. Faxed draft or informal communications with the examiner should be directed to (571) 273-0876.

Information regarding the status of an application may be obtained from the Patent application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Prema Mertz Ph.D., J.D. Primary Examiner Art Unit 1646 February 15, 2007